Flagship’s gene editing startup Tessera cuts jobs as it shifts resources to clinic

Tessera Ther­a­peu­tics, Flag­ship’s ma­jor bet on what it calls gene writ­ing, is let­ting go 13% to 14% of its work­force, a spokesper­son con­firmed to End­points News.

The well-fund­ed Boston biotech will re­duce its head­count as it fo­cus­es on get­ting in­to the clin­ic. The spokesper­son said the move im­pacts “less than 50 em­ploy­ees.”

“As a re­sult of pos­i­tive da­ta from our pre­clin­i­cal pro­grams, we have reached an in­flec­tion point where we need to re­bal­ance the re­sources of our or­ga­ni­za­tion to pri­or­i­tize and grow our clin­i­cal de­vel­op­ment ef­forts in an­tic­i­pa­tion of ad­vanc­ing mul­ti­ple can­di­dates in­to the clin­ic,” the spokesper­son wrote in an email.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.